Table 1.
Phenotypic and molecular characterization of the four new subtypes.
| Characteristic a | Lymphoma subtype | p-value b | |||||
|---|---|---|---|---|---|---|---|
| mBL* | intermediate A | intermediate B | non-mBL * | ||||
| Total | number of patients | 221 | 62 (28%) | 42 (19%) | 44 (20%) | 73 (33%) | |
| Age | <20 y | 32 (14%) | 26 (42%) | 0 (0%) | 1 (2%) | 5 (7%) | <0.001 |
| 21–65 y | 92 (42%) | 27 (44%) | 14 (33%) | 22 (50%) | 29 (40%) | ||
| >66 y | 95 (43%) | 9 (15%) | 27 (64%) | 20 (45%) | 39 (53%) | ||
| Gender | male | 127 (57%) | 40 (65%) | 26 (62%) | 23 (52%) | 38 (52%) | 0.44 |
| female | 91 (41%) | 22 (35%) | 15 (36%) | 20 (45%) | 34 (47%) | ||
| Diagnosis | Burkitt's lymphoma | 15 (7%) | 15 (24%) | 0 (0%) | 0 (0%) | 0 (0%) | <0.001 |
| Atypical Burkitt’s lymphoma | 20 (9%) | 16 (26%) | 3 (7%) | 0 (0%) | 1 (1%) | ||
| Diffuse large-B-cell lymphoma | 164 (74%) | 24 (39%) | 37 (88%) | 38 (86%) | 65 (89%) | ||
| Mature aggressive B-cell lymphoma, unclassifiable | 18 (8%) | 5 (8%) | 2 (5%) | 5 (11%) | 6 (8%) | ||
| Ann Arbor stage | I or II | 72 (33%) | 25 (40%) | 9 (21%) | 15 (34%) | 23 (32%) | 0.37 |
| III or IV | 82 (37%) | 19 (31%) | 15 (36%) | 22 (50%) | 26 (36%) | ||
| Response to treatment | Complete remission | 68 (31%) | 27 (44%) | 8 (19%) | 10 (23%) | 23 (32%) | 0.40 |
| Complete remission, unconfirmed | 18 (8%) | 4 (6%) | 2 (5%) | 6 (14%) | 6 (8%) | ||
| No change | 2 (1%) | 0 (0%) | 0 (0%) | 1 (2%) | 1 (1%) | ||
| Partial response | 16 (7%) | 1 (2%) | 3 (7%) | 5 (11%) | 7 (10%) | ||
| Progress | 24 (11%) | 7 (11%) | 4 (10%) | 7 (16%) | 6 (8%) | ||
| Molecular classification | mBL | 44 (20%) | 44 (71%) | 0 (0%) | 0 (0%) | 0 (0%) | <0.001 |
| Hummel et al. [10] | intermediate | 48 (22%) | 18 (29%) | 11 (26%) | 10 (23%) | 9 (12%) | |
| non-mBL | 129 (58%) | 0 (0%) | 31 (74%) | 34 (77%) | 64 (88%) | ||
| GCB-ABC classification | Activated B-cells | 58 (26%) | 2 (3%) | 26 (62%) | 15 (34%) | 15 (21%) | <0.001 |
| Wright et al. [45] | Germinal center B-cells | 120 (54%) | 53 (85%) | 10 (24%) | 18 (41%) | 39 (53%) | |
| unclassified | 43 (19%) | 7 (11%) | 6 (14%) | 11 (25%) | 19 (26%) | ||
| Translocations | |||||||
| MYC translocation | IG-MYC | 60 (27%) | 49 (79%) | 1 (2%) | 6 (14%) | 4 (5%) | <0.001 |
| non-IG-MYC | 15 (7%) | 6 (10%) | 5 (12%) | 2 (5%) | 2 (3%) | ||
| neg | 144 (65%) | 7 (11%) | 36 (86%) | 35 (80%) | 66 (90%) | ||
| BCL6 Break | pos | 37 (17%) | 2 (3%) | 9 (21%) | 11 (25%) | 15 (21%) | 0.002 |
| neg | 179 (81%) | 59 (95%) | 32 (76%) | 31 (70%) | 57 (78%) | ||
| IGH Break | pos | 115 (52%) | 53 (85%) | 11 (26%) | 23 (52%) | 28 (38%) | <0.001 |
| neg | 103 (47%) | 9 (15%) | 30 (71%) | 20 (45%) | 44 (60%) | ||
| t(14;18) translocation | pos | 25 (11%) | 5 (8%) | 2 (5%) | 6 (14%) | 12 (16%) | 0.19 |
| neg | 193 (87%) | 57 (92%) | 40 (95%) | 37 (84%) | 59 (81%) | ||
| Immunohisto-chemistry | |||||||
| CD10 | low | 114 (52%) | 3 (5%) | 33 (79%) | 26 (59%) | 52 (71%) | <0.001 |
| high | 96 (43%) | 56 (90%) | 6 (14%) | 14 (32%) | 20 (27%) | ||
| BCL2 | low | 62 (28%) | 38 (61%) | 2 (5%) | 7 (16%) | 15 (21%) | <0.001 |
| high | 153 (69%) | 22 (35%) | 39 (93%) | 35 (80%) | 57 (78%) | ||
| BCL6 | low | 34 (15%) | 5 (8%) | 9 (21%) | 7 (16%) | 13 (18%) | 0.21 |
| high | 168 (76%) | 52 (84%) | 29 (69%) | 32 (73%) | 55 (75%) | ||
| MUM1 | low | 66 (30%) | 29 (47%) | 7 (17%) | 8 (18%) | 22 (30%) | 0.001 |
| high | 139 (63%) | 27 (44%) | 33 (79%) | 32 (73%) | 47 (64%) | ||
| KI67 | low | 125 (57%) | 17 (27%) | 26 (62%) | 26 (59%) | 56 (77%) | <0.001 |
| high | 89 (40%) | 44 (71%) | 15 (36%) | 14 (32%) | 16 (22%) | ||
a Percentages refer to the total number of samples. Parameters are not available for all samples. Data are taken from ref [43]; b p-values are calculated using Fisher’s exact test.